In vivo and ex vivo analyses of amyloid toxicity in the Tc1 mouse model of Down syndromeMore about Open Access at the Crick
Authors listGaëlle Naert Valentine Ferré Emeline Keller Amy Slender Dorota Gibbins Elizabeth MC Fisher Victor Tybulewicz Tangui Maurice
The prevalence of Alzheimer's disease is increased in people with Down syndrome. The pathology appears much earlier than in the general population, suggesting a predisposition to develop Alzheimer's disease. Down syndrome results from trisomy of human chromosome 21, leading to overexpression of possible Alzheimer's disease candidate genes, such as amyloid precursor protein gene. To better understand how the Down syndrome context results in increased vulnerability to Alzheimer's disease, we analysed amyloid-β [25-35] peptide toxicity in the Tc1 mouse model of Down syndrome, in which ~75% of protein coding genes are functionally trisomic but, importantly, not amyloid precursor protein.
Journal Journal of Psychopharmacology
Issue number 2